Key statistics dashboard for Dogwood Therapeutics, Inc. (DWTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia.
Stock Data
| Price | $1.70 |
| Market Cap | $57M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.19 |
| Price / Book | 0.86 |
| P/S | 0.00 |
| P/FCF | -3.85 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.89 |
| Quick Ratio | 3.89 |
| Cash Ratio | 3.39 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.16% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.29 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.00 |
| Cash per share | 0.28 |
| FCF per share | -0.44 |
| Tangible Book Value per share | -0.03 |
| Dividend per share | 0.00 |
Related companies: BOLT · BRTX · CLRB · COCP · EDSA · ERNA · EVGN
Explore sector: Healthcare · Biotechnology
More sections of DWTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks